UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments. Issue 43 (8th October 2019)

• Record Type: Journal Article
• Authors: Noad, Rob J.; Simpson, Karl; Fooks, Anthony R.; Hewson, Roger; Gilbert, Sarah C.; Stevens, Mark P.; Hosie, Margaret J.; Prior, Joann; Kinsey, Anna M.; Entrican, Gary; Simpson, Andrew; Whitty, Christopher J.M.; Carroll, Miles W
• Is Part Of: Vaccine. Volume 37:Issue 43(2019)
• Page Start: 6241
• Page End: 6247
• Publication Date: 2019-10-08
• Subjects: CEPI Coalition for Epidemic Preparedness Innovations -- CHIKV Chikungunya virus -- CCHF Crimean-Congo Haemorrhagic Fever -- MERS Middle East Respiratory Syndrome -- MVA Modified vaccinia virus Ankara -- NCBI National Centre for Biotechnology Information -- NIAID US National Institute of Allergy and Infectious Diseases -- SARS Severe Acute Respiratory Syndrome -- UKVN UK Vaccine Research and Development Network -- VSV Vesicular Stomatitis Virus -- WHO World Health Organisation; Vaccine -- Epidemic -- Priority -- Pathogen -- Outbreak -- UKVN; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2019.09.009
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: During the 2013–2016 Ebola outbreak in West Africa an expert panel was established on the instructions of the UK Prime Minister to identify priority pathogens for outbreak diseases that had the potential to cause future epidemics. A total of 13 priority pathogens were identified, which led to the prioritisation of spending in emerging diseases vaccine research and development from the UK. This meeting report summarises the process used to develop the UK pathogen priority list, compares it to lists generated by other organisations (World Health Organisation, National Institutes of Allergy and Infectious Diseases) and summarises clinical progress towards the development of vaccines against priority diseases. There is clear technical progress towards the development of vaccines. However, the availability of these vaccines will be dependent on sustained funding for clinical trials and the preparation of clinically acceptable manufactured material during inter-epidemic periods.